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Abstract
Purpose—Experimental studies demonstrate that ω-3 polyunsaturated fatty acids (PUFAs) 
inhibit inflammatory eicosanoids generated by ω-6 PUFAs. Epidemiologic studies on dietary ω-3 
PUFA intake show consistent inverse associations with breast cancer incidence among Asian 
populations, where ω-3, relative to ω-6, intake is high. In contrast, associations are inconsistent 
among Western populations, where intake of ω-3, relative to ω-6, intake is low. We hypothesized 
that examining interactions between ω-3 and ω-6 would help elucidate the PUFA-breast cancer 
association in the U.S.
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Methods—In a Long Island, NY, population-based study of 1463 breast cancer cases and 1500 
controls, we estimated multivariable-adjusted odds ratios (ORs) and 95% confidence intervals 
(CIs) using unconditional logistic regression to examine interactions between ω-3 and ω-6 intake.
Results—We observed a super-additive interaction (Relative Excess Risk Due to 
Interaction=0.41; 95%CI=0.06,0.76) between ω-3 and ω-6 intake in association with breast cancer 
incidence, although the CIs for the joint exposure of low ω-3/high ω-6 compared to high ω-3/low 
ω-6 intake were wide (OR=1.20; 95%CI=0.85,1.69).
Conclusions—Breast cancer risk reduction may be possible for U.S. women with dietary 
consumption of higher ω-3, which have anti-inflammatory properties, in concert with lower ω-6, 
which induce inflammation. Replication from future U.S.-based investigations is needed.
Keywords
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Introduction
Breast cancer incidence rates are more than two times higher in the United States (U.S.) and 
European countries than in China or Japan [1,2]. Migration studies conducted among Asian 
immigrants show that breast cancer incidence patterns begin to reach those of Western 
countries a few generations after migration [3–6], suggesting environmental factors may 
play a role in the geographic variation in incidence rates observed in Asian and Western 
countries.
One potential environmental exposure is polyunsaturated fatty acids (PUFAs), which 
includes two primary classes, ω-3 and ω-6 fatty acids. Laboratory studies show that ω-3 
PUFAs competitively inhibit ω-6 fatty acids, thus lowering levels of inflammatory 
eicosanoids generated from ω-6 metabolism [7], and that higher ω-3 relative to ω-6 could 
reduce breast cancer through inflammation, oxidative stress, and estrogen metabolism [7–
10]. Asian populations have a substantially higher ratio of ω-3/ω-6 intake compared to 
European and U.S. populations [11,12], due to higher fish consumption [13–15], which may 
partially explain the lower breast cancer risk observed in these populations [16–19]. 
However, previous U.S. and European epidemiologic studies examining the PUFA and 
breast cancer association remain inconsistent [20–40]. The biologic influence of PUFAs is 
unlikely to differ across populations; however, low fish intake and high ω-6 intake [41] in 
Western countries may mask important risk reductions. We hypothesized that consideration 
of both ω-3 and ω-6 intake, as an interaction or as the relative balance (ω-3/ω-6 ratio), may 
elucidate the potential benefit of ω-3 intake among populations with low fish consumption.
In the study reported here, we examined the interaction between dietary ω-3 and ω-6 PUFA 
classes in association with breast cancer risk among women on Long Island, New York 
(NY).
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We used the population-based case-control component of the Long Island Breast Cancer 
Study Project (LIBCSP) comprising English-speaking residents of Nassau and Suffolk 
counties. Details of the LIBCSP have been published previously [42]. Institutional Review 
Board approval was obtained from all participating institutions.
Study population
Cases were women newly diagnosed with a first primary in situ or invasive breast cancer, 
identified using a “super-rapid” network by contacting hospital pathology departments daily 
or 2-3 per week. Controls were identified using Waksberg’s method of random digit dialing 
[43] for women under 65 years of age, and Health Care Finance Administration rosters for 
women 65 years and older. Controls were frequency matched to the expected age-
distribution of cases. There were no age or race restrictions for subject eligibility.
The parent LIBCSP respondents included 1,508 cases and 1,556 controls (82% and 63% 
response rates, respectively). Respondents ranged in age from 20 to 98 years of age, 67% 
were postmenopausal, and the majority self-reported their race as white (94%), followed by 
black or African American (4%), or other (2%), which is consistent with the racial 
distribution of these two counties at the time of data collection [44]. Most LIBCSP 
participants were highly educated (>90% graduating from high school), used alcohol (62%), 
were parous (88%), never used hormone replacement therapy (74%), never used oral 
contraceptives (55%), and did not have a family history of breast cancer (84%). Among 
cases, the majority (84%) were diagnosed with first, primary invasive breast cancer [42].
Assessment of PUFAs and other covariates
LIBCSP participants were administered a main risk factor questionnaire by a trained 
interviewer about 3 months after diagnosis for cases and 5.5 months after identification for 
controls [42]. Approximately 98% of participants (1,479 cases and 1,520 controls) also 
completed the validated [45–47] self-administered 101-item modified Block food frequency 
questionnaire (FFQ). After excluding participants with implausible total energy intake (±3 
standard deviations from the mean; n=36), 1,463 cases and 1,500 controls remained in our 
analysis.
We estimated PUFA intake by linking responses from the FFQ (i.e., grams per day for each 
line item) with nutrient values available in the U.S. Department of Agriculture databases for 
ω-3 and ω-6 PUFAs [48]. The following PUFAs were estimated: (1) ω-3 fatty acids, 
including alpha-linolenic acid (ALA), docosapentaenoic acid (DPA), docosahexaenoic acid 
(DHA), eicosapentaenoic acid (EPA); and (2) ω-6 fatty acids, including linoleic acid (LA) 
and arachidonic acid (AA). An estimate of total PUFA intake was calculated by combining 
all individual fatty acids. Additionally, an estimate of total ω-3 and ω-6 fatty acids was 
obtained by summing each individual fatty acid within category (e.g., total ω-3=ALA + 
DPA + DHA + EPA). We also examined fish/seafood intake according to the items recorded 
in the FFQ: (1) tuna, tuna salad, tuna casserole; (2) shell fish (shrimp, lobster, crab, oysters, 
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etc.); and (3) other fish (either broiled/baked). Total fish intake was calculated by summing 
each of the fish/seafood items recorded in the FFQ.
Statistical analyses
All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC). 
Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% 
confidence intervals (95%CI) for the association between PUFA intake and breast cancer 
risk. PUFA and fish/seafood intake were categorized as quartiles, according to the 
distribution among controls. Quartiles were selected over other methods of categorization 
(e.g., tertiles, quintiles, linear, splines) because the shape of the dose-response between 
exposure and breast cancer incidence was best represented using these cut-points. The 
relation between any of the PUFA and/or fish and breast cancer incidence was not strictly 
monotonic [49] thus linear trend tests were not conducted.
Interactions between total ω-3 and total ω-6 intake in association with breast cancer 
incidence were assessed on the additive (common referent) and multiplicative scales. 
Additive interaction was evaluated using relative excess risk due to interaction (RERI), with 
95% CI [50]. Multiplicative interactions were evaluated by comparing nested models using 
the Likelihood Ratio Test (LRT) [49]. Total ω-3, total ω-6, and ω-3/ω-6 ratio were 
dichotomized at the median for use in the interaction models.
We also considered effect modification of the association between PUFA intake and breast 
cancer risk by: menopausal status (post- vs. pre-menopausal status); and dietary supplement 
use (yes/no). However, little or no heterogeneity was observed with either of these 
covariates (data not shown). We also considered potential heterogeneity across breast cancer 
subtypes, defined by hormone receptor status (any hormone receptor positive breast cancer 
vs. no hormone receptor positive breast cancer), by constructing polytomous regression 
models; however, no differences were observed across hormone receptor subtype (data not 
shown).
All models were adjusted for the frequency matching factor five-year age group. Other 
potential confounders (including total energy intake, non-steroidal anti-inflammatory drugs 
(NSAID), family history of breast cancer, income, body mass index, alcohol use, fruit and 
vegetable intake, and physical activity) were identified using directed acyclic graph [49]. 
The only covariate that changed the estimates by more than 10% was total energy intake for 
PUFA intake. All fish intake models included age, energy intake and NSAID use given the 
possibility that chronic NSAID users experience gastrointestinal problems (e.g., stomach 
ulcers, reflux) which may subsequently influence diet, including fish consumption [51].
Results
As presented in Table 1, the average intake of total ω-3 fatty acids (1.01 grams per day 
(SD=0.74)) was lower relative to ω-6 intake [7.66 grams per day (SD=5.68)] among the 
1,500 control women in this population-based sample of Long Island residents. The highest 
contributor to total ω-3 intake was ALA with average intake of 0.86 grams per day 
(SD=0.71), whereas LA was the highest contributor to total ω-6 intake with an average 
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intake of 7.59 grams per day (SD=5.66). Tuna intake was reported at higher levels [8.80 
grams per day (SD=13.98)] in our control population compared to shell fish intake [3.57 
grams per day (SD=9.07)]. Fish was a major contributor to high intake of long-chain ω-3 
PUFAs, including DPA, DHA, and EPA. In contrast, foods that contributed to high ALA 
intake were biscuits/muffins and other fried foods, which was similar to what was observed 
for LA intake. High AA intake appeared to be driven by eggs and meats, including fish, 
chicken, and ham.
Multivariable-adjusted odds ratios for the associations between all measures of PUFA intake 
and breast cancer incidence were imprecise (and most were not statistically significant), as 
presented in Table 2. For example, elevated odds ratios were observed for high intake of 
total PUFA, total ω-3, ALA, ω-6, and LA intakes, but CIs were wide. No associations were 
observed for the long-chain ω-3 PUFA (DPA, DHA, EPA), AA, or high intake of the 
ω-3/ω-6 ratio.
As shown in Table 3, we observed an interaction between ω-3 and ω-6 intake, which was 
statistically significant on the additive scale [adjusted RERI=0.41 (95%CI=0.06,0.76)]. Risk 
reductions for breast cancer were modest for women who consumed low levels of both ω-3 
and ω-6 [adjusted OR=0.83 (95%CI=0.63,1.09)], compared to women who consumed high 
ω-3 and low ω-6. For women who consumed high levels of ω-3 and ω-6, the odds ratios 
were close to the null value [adjusted OR=0.95 (95%CI=0.72,1.26)]. In contrast, higher 
intakes of ω-6 fatty acids in conjunction with lower intake of ω-3 fatty acids was associated 
with an approximately 20% increased breast cancer incidence [adjusted OR=1.20 (95% 
CI=0.85,1.69)]. The increase observed for this group was super-additive (41% greater) 
compared to the 22% (=5%+17%) expected risk reduction, derived from the individual ORs 
for those consuming either high levels (≥median; 5% risk reduction), or low levels 
(<median; 17% risk reduction) of both ω-3 and ω-6 fatty acids. Similar results were 
observed when we considered interactions between ω-3 and ω-6 on a multiplicative scale, as 
shown in Table 4.
Higher intake of total fish, tuna, shell fish, or other fish (broiled/baked) was not associated 
with breast cancer risk in our study, as presented in Table 5.
Discussion
We are the first to report an additive interaction between ω-3 intake and ω-6 intake in 
relation to breast cancer risk in a population-based sample of U.S women. Specifically, we 
observed a 20% increase in the odds of breast cancer among consumers of high levels of ω-6 
and low levels of ω-3 compared to those who consumed low levels of ω-6 and high levels of 
ω-3. The odds ratio for women consuming high ω-6 and low ω-3 was increased, whereas the 
corresponding estimates for intake of high levels or low levels, of either PUFA class, were 
reduced. This interaction underscores the importance of considering intake of ω-3 and ω-6 
simultaneously when examining associations with breast cancer in the U.S.
No previous U.S. studies have reported the potential interaction between ω-3 and ω-6 
PUFAs and breast cancer risk, and only two examined the ratio of ω-3 and ω-6 intakes 
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[23,30]. Consideration of an interaction may be preferable, given that a ratio measure 
permits only one type of relation between two exposures, whereas an interaction is more 
flexible. One previous Shanghai study reported an interaction between ω-3 and ω-6 intake 
on breast cancer risk [18], with a significant two-fold increased risk for high ω-6 in 
combination with low marine-derived ω-3 intake. The LIBCSP results presented here for the 
interaction between ω-3 and ω-6 intake are in the same direction as those reported in the 
Shanghai study, but less pronounced. Importantly, daily fish consumption in the Shanghai 
population was almost five times greater than the frequency reported among our Long Island 
population, which could partially explain the weaker association observed in our study.
The modest positive association between ω-6 PUFA (total ω-6, LA, AA) and breast cancer 
incidence observed here is similar to associations reported in other studies conducted among 
Western populations [16,18,28,30,35]. However, our findings for the association between 
long-chain ω-3 (DPA, DHA, EPA) PUFAs are not consistent with the risk reductions 
reported by previous studies conducted among Asian and some European populations [16–
19,32]. Additionally, the increased risk for ALA intake we observed is inconsistent with the 
laboratory evidence for inhibition of breast cancer growth [52,53]. However, in other 
epidemiologic studies, the association between ALA intake and breast cancer risk remains 
unclear, with some studies reporting increased risks [18,20,29,32,54], and others reporting 
risk reductions [24,36]. The variation in results across studies may be due to different 
dietary assessment methods used, consumption of different food sources of ALA (e.g., 
biscuits/muffins and fried foods were major contributors in our population), or with potential 
recall bias that can occur in case-control studies. Or, perhaps, ALA reduces breast cancer 
growth only after conversion to long-chain ω-3 PUFAs. The in vivo conversion of ALA to 
long-chain ω-3 PUFAs is inefficient in the presence of high ω-6 [55]. Thus, it is possible 
that in populations with high ω-6 intake, benefits of ALA intake are less evident.
The slight breast cancer risk reductions in relation to a high ω-3/ω-6 ratio observed in our 
study were modest compared to estimates reported in other studies in European [56], 
Mexican [57], and U.S. populations [23,30]. However, this may reflect the relatively low 
intake of ω-3 and ω-6 in our study population. Very low intake of both ω-3 and ω-6 PUFAs 
could result in a high ratio value for ω-3/ω-6 intake (when ω-6 intake is less than 1). Doses 
in excess of 2 g/day may be required for decreasing prostaglandin E2 production [58,59], a 
primary inflammatory eicosanoid resulting from AA metabolism, which has been implicated 
in carcinogenesis [7]. Thus, a high ratio of ω-3/ω-6 derived from low intakes of ω-3 and ω-6 
PUFAs may not represent a sufficient dose for ω-3 to exert a beneficial response in vivo. In 
the U.S., only one previous population-based study has considered the PUFA ratio in 
association with breast cancer risk; utilizing data from the Vitamins and Lifestyle Cohort 
(VITAL) [30], a 16% risk reduction was observed in association with high ω-3/ω-6 intake 
ratio. This Western Washington-based study included marine-derived ω-3 intake from both 
dietary sources and supplements, and thus levels of ω-3 intake were higher than the dietary-
derived intake estimates observed in our Long Island-based study. Nonetheless, given the 
modest risk reductions reported for the ω-3/ω-6 ratio in both studies, examining the 
interaction between ω-3 and ω-6 intake, rather than the ratio, may be a more favorable 
strategy in populations where PUFA intake is relatively low.
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Strengths of our population-based, case-control study include observation of an interaction 
between ω-3 and ω-6 on breast cancer development, which has not been previously assessed 
in a U.S. population. We also examined associations with fish intake (a dietary source rich 
in ω-3 fatty acids) among women who reside in a geographic area that is surrounded by 
water, and for whom the variability of fish intake would presumably be greater than for 
others who reside in more land-locked areas of the U.S [14]. However, we did not observe 
any notable associations with fish intake and breast cancer incidence, even though women 
living in New York City [60] have been reported to consume fish greater than the national 
estimates from NHANES [61].
This study also has limitations. The LIBCSP population includes predominantly Caucasian 
women, which reflects the racial distribution of the residents of the two source counties on 
Long Island. Consequently, examination of racial differences was not possible. Our results 
are therefore generalizable to only Caucasian-American women, for whom breast cancer 
risk remains high [62].Future studies may also be warranted to evaluate the timing of 
exposure relative to breast cancer development. FFQ responses are assumed to reflect usual 
adult diet [63], although recent changes due to a disease diagnosis or treatment regimens 
could influence those responses. The LIBCSP questionnaires were administered within 
months of diagnosis, and for two-thirds of women this was prior to the onset of 
chemotherapy [42], which is likely to reduce the impact of dietary changes and perhaps 
recall of diet on the FFQ. However, a single dietary assessment via FFQ may not necessarily 
reflect diet during all etiologically relevant time periods for breast cancer development (i.e., 
adolescence) [64].
Furthermore, estimating PUFA intake via FFQ linkage with the USDA databases could 
result in measurement error. For example, the PUFA content measured in the foods reported 
in the USDA database [48] may differ from those actually consumed by LIBCSP 
participants due to differences in harvesting, storage, processing, and cooking methods [65–
67]. Additionally, we were unable to assess associations with consumption of different fish 
varieties. This is important given the amount of long-chain ω-3 content found in fish differs 
by species [61]. However, we assessed tuna intake, which is the most frequently consumed 
fish variety in the U.S. and is also a major source of dietary ω-3s [14]. PUFA intake via 
supplements (i.e., fish oil consumption) was not measured as part of the case-control 
interview. Given fish oil contributes to intake of long-chain ω-3 this could underestimate 
DHA and EPA consumption in our population. However, in a follow-up interview, 89% of 
the LIBCSP cases reported never using fish oil supplements approximately five years after 
diagnosis [68]. Fish oil supplement use has only recently (after 2002) received attention due 
to is potential risk reductions for cardiovascular disease [69]. Furthermore, use of fish oil 
supplements increased post-2002 in two large U.S. cohorts [70]. Thus, prevalence of fish oil 
supplement use at the time of the LIBCSP case-control interview (during years 1996-1997) 
was likely low and the potential underestimation of DHA and EPA intake may be negligible. 
Biomarkers could provide an objective measure of PUFA intake; however, biomarkers may 
reflect different time periods of exposure, ranging from a few days to one year (depending 
on the type of biomarker used) [71]. Therefore, use of PUFA biomarker measurements in a 
case-control study may not reflect the etiologically relevant time period for breast cancer 
development. Future studies, if feasible, should consider multiple prospective biomarker 
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measurements in order to capture dietary PUFA exposure (including changes in diet) during 
relevant periods of breast cancer etiology.
In conclusion, we observed among a population-based sample of Long Island residents, 
women who consume high levels of ω-6 and low levels of ω-3 had an increased risk for 
breast cancer, compared to women who consume low levels of ω-6 and high levels of ω-3. 
Our results suggest that high intake of ω-3 PUFA, coupled with low intake of ω-6, may be a 
potential risk reduction strategy for breast cancer among U.S. women. Further confirmation 
using an objective measurement of PUFA intake via biomarkers may be warranted.
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Table 1
Characteristics of polyunsaturated fatty acid intake (PUFA) and fish intake among the population-based 
sample of control women (N=1500) in the LIBCSP, 1996-1997
Nutrient/Food Mean SD
Quartile
Cutpoints Major PUFA-rich foods contributing



















DPA 0.01 0.01 0.01 0.01 0.02 Tuna, fish, chicken, shellfish, beef
DHA 0.09 0.09 0.03 0.06 0.12 Tuna, fish, eggs, shellfish, chicken
EPA 0.04 0.05 0.01 0.03 0.06 Fish, tuna, shellfish, chicken








AA 0.07 0.06 0.04 0.06 0.09 Eggs, Fish, chicken, ham/lunch meats,shellfish
ω-3/ω-6 0.15 0.14 0.10 0.14 0.17 N/A
Fish (g/day) d
Total fishe 19.62 23.83 4.87 13.23 26.86 N/A
Tuna 8.80 13.98 0.00 4.77 12.40 N/A
Shell fish 3.57 9.07 0.00 0.00 4.62 N/A
Other
(broiled/baked) 7.25 10.59 0.00 2.80 10.77 N/A
Note:
a
Total PUFA = ALA + DPA + DHA + EPA + LA + AA
b
Total ω-3 = ALA + DPA + DHA + EPA
c
Total ω-6 = LA + AA
d
Controls with null values for total fish (N=161), tuna (N=393), shell fish (N=765), and other (N=592) were included in calculations.
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e
Total fish = tuna + shell fish + other (broiled/baked)
LIBCSP = Long Island Breast Cancer Study Project
SD = standard deviation
N/A = not applicable
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Table 4
Multivariablea-adjusted ORs and 95% CI for the multiplicative interaction between dietary ω-3 and ω-6 (high 









N OR 95% CI N OR 95% CI
High ω-3 (≥ median) 256 1.00 1,214 1.00
Low ω-3 (< median) 1,215 0.83 0.63, 1.09 278 1.26 0.96, 1.65 4.61 0.03
Note:
Co=Controls, Ca=Cases, LIBCSP=Long Island Breast Cancer Study Project, LRT=likelihood ratio test
a
Multivariable ORs and 95% CI adjusted for matching factor (5-year age group) and total energy intake (kcal/day)
b
LRT χ2 calculated using nested models for the multiplicative interaction.
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